Patent and Innovation Trends in GLP-1 and Weight Loss Drugs (20202025): What the IP and Science Signal Next This article was powered by Cypris Q, an AI agent that helps R&D teams instantly synthesize insights from patents, scientific literature, and market intelligence from around the globe
Her story on the podcast This American Life unpacked the questions that haunted her long after the dramatic makeover was complete
#Day241 #ClinicalFact #IndiaPharma2026 #DrugDiscovery #Biosimilars #ViksitBharat #Pharmaceuticals #MedicalInnovation #PharmD #GlobalHealth To view or add a comment, sign in Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S
Triple-hormone-receptor agonist retatrutide for obesity - a Phase 2 trial
11 Table 2: The Semaglutide Patent Fortress Source: 19 Do you see the gap
Decisions related to weight management, metabolic health, and nutritional supplementation should be made in partnership with a licensed clinician familiar with your individual health needs